Trask Adam Roland
- SEC CIK
- 0002109050
- Latest filing
- May 15, 2026
The latest 13F from Trask Adam Roland covers Q1 2026 (filed May 15, 2026): 190 long positions worth $105.7M. The top 10 holdings make up 49.0% of the portfolio, and the largest is Eli Lilly & Co (LLY) at 7.2%. Livermore has 1 filing on Form 13F from this institution, going back to Q1 2026.
What changed in Q1 2026
The five largest holdings this quarter.
Trask Adam Roland did not file a 13F for Q4 2025, so this quarter cannot be compared with the previous one.
Metrics
13F metrics for Q1 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $105.7M
- No prior quarter to compare
- Positions
- 190
- No prior quarter to compare
- Top 10 concentration
- 49.0%
- Top 10 as share of value
- Turnover
- –
- No prior quarter to compare
- Average holding period
- 1.0 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2026), so positions held before then are understated.
13F filings by quarter
Only Q1 2026 so far.